Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study.

"Disclosures MK received speaker honoraria from Medtronic. LHB received personal fees from Claret Medical and InnovHeart. UF reports research grants from Medtronic for the SWIFT DIRECT trial (Solitaire With the Intention for Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke) and BEYOND SWIFT registry (Registry for Evaluating Outcome of Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy); consulting fees from Medtronic, Stryker and CSL Behring (fees paid to institution); membership of a Data Safety Monitoring Board for the IN EXTREMIS trial (Large Stroke Therapy Evaluation) and TITAN trial (Thrombectomy in Tandem Occlusion). GMDM received speaker honoraria from Medtronic. The other authors report no conflicts of interest."

"Sources of Funding The study was funded by the University Hospital Basel and the Propatient Research Foundation (PRF). The funders (University Hospital Basel, PRF) did not influence the design of the study, data collection, or analysis of the data."

"This multicenter cohort study was performed using data from 5 certified Swiss stroke centers capable of MT from the prospective Swiss Stroke Registry (EKNZ UBE 15/30). Outcome measures are prospectively recorded by qualified personnel. Inclusion criteria were a LVO diagnosis confirmed by computer tomography (CT) or magnetic resonance imaging (MRI) angiography (ie, internal carotid artery, M1 or M2 segment of the middle cerebral artery), admission between 6 and 24 hours after last-seen-well, and availability of perfusion imaging source data (CT or MRI). We excluded patients who had no available perfusion imaging and those with withdrawn research consent."